Reply to Chu et al., "Adoption of the New CLSI Fluoroquinolone Breakpoints for Enterobacteriaceae"

Tam T Van^{1

2}, Emi Minejima³, Chiao An Chiu³, Susan M Butler-Wu⁴

Affiliations

¹ Department of Pathology, Harbor-UCLA Medical Center, Torrance, California, USA.
² Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
³ Department of Clinical Pharmacy, USC School of Pharmacy, Los Angeles, California, USA.
⁴ Department of Pathology and Laboratory Medicine, Keck School of Medicine of USC, Los Angeles, California, USA butlerwu@usc.edu.

Comment

Tam T Van et al. J Clin Microbiol. 2019.

. 2019 Oct 23;57(11):e01268-19.

doi: 10.1128/JCM.01268-19. Print 2019 Nov.

Tam T Van^{1

2}, Emi Minejima³, Chiao An Chiu³, Susan M Butler-Wu⁴

¹ Department of Pathology, Harbor-UCLA Medical Center, Torrance, California, USA.
² Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
³ Department of Clinical Pharmacy, USC School of Pharmacy, Los Angeles, California, USA.
⁴ Department of Pathology and Laboratory Medicine, Keck School of Medicine of USC, Los Angeles, California, USA butlerwu@usc.edu.

No abstract available

Comment on

Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
Van TT, Minejima E, Chiu CA, Butler-Wu SM. Van TT, et al. J Clin Microbiol. 2019 Jun 25;57(7):e02072-18. doi: 10.1128/JCM.02072-18. Print 2019 Jul. J Clin Microbiol. 2019. PMID: 31043468 Free PMC article. Review.
Adoption of the New CLSI Fluoroquinolone Breakpoints for Enterobacteriaceae.
Chu YW, Tse H, Tsang D. Chu YW, et al. J Clin Microbiol. 2019 Oct 23;57(11):e01176-19. doi: 10.1128/JCM.01176-19. Print 2019 Nov. J Clin Microbiol. 2019. PMID: 31645411 Free PMC article. No abstract available.

1. Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.
1. Van TT, Minejima E, Chiu CA, Butler-Wu SM. 2019. Don’t get wound up: revised fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 57:e02072-18. doi:10.1128/JCM.02072-18. - DOI - PMC - PubMed
1. Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P. 1999. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 37:3572–3577. - PMC - PubMed
1. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. 2003. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 37:75–81. doi:10.1086/375602. - DOI - PubMed
1. Vasallo FJ, Martín-Rabadán P, Alcalá L, García-Lechuz JM, Rodríguez-Créixems M, Bouza E. 1998. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin Infect Dis 26:535–536. doi:10.1086/517087. - DOI - PubMed